TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06682130
Drug: Group C: Patients with SD/PD after posterior treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group C: cycle1 2.5mg day8, 10mg day15 cycle2 30mg day21~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6;~After two treatment cycles with Glofitamab, patients in group C had a PET-CT to assess efficacy. Those with partial remission proceeded to ASCT consolidation, those with complete remission chose between ASCT or Glofitamab maintenance, and those with stable disease or progressive disease exited the trial.
Study: NCT05204927
Drug: 177Lu-PSMA-I&T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand therapy
Study: NCT06665087
Drug: Ultrafractionated RT and CGA Guided systemic treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed, with/without targeted therapy, and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, with/without targeted therapy, and BSC.
Study: NCT06665087
Drug: Targeted Therapy (anti-VEGF)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-VEGF antibody
Study: NCT06665087
Drug: Targeted Therapy (anti-EGFR)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-EGFR antibody
Study: NCT06058520
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product.
Study: NCT05420584
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.
Study: NCT04837508
Drug: MRG002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated intravenously
Study: NCT03843463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic escitalopram 10 mg tablet
Study: NCT06682546
Drug: ET-26HCl 0.6mg/kg group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose is 0.6 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion). Infusion time was 1minute ± 5second.
Study: NCT06682546
Drug: ET-26HCl 0.8mg/kg group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose is 0.8 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion). Infusion time was 1minute ± 5second.
Study: NCT05751512
Drug: Methotrexate Injection
Normalized name: methotrexate Injection
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05497479
Drug: 0.003% AR-15512 to be administered in both eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two rounds of Schirmer tests, performed without anesthetic (per randomization), before and after instillation of 0.003% AR-15512
Study: NCT05497479
Drug: Vehicle to be administered in both eyes
Normalized name: Born To Be Mild
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two rounds of Schirmer tests, performed without anesthetic, before and after instillation of Vehicle
Study: NCT05497479
Drug: 0.003% AR-15512 to be administered in both eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of 0.003% AR-15512
Study: NCT05497479
Drug: Vehicle to be administered in both eyes
Normalized name: Born To Be Mild
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of Vehicle
Study: NCT06682611
Drug: HB1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: In accordance with the protocol
Study: NCT05720130
Drug: [²¹²Pb]Pb-ADVC001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ph1b Escalation~Drug: \[²¹²Pb\]Pb-ADVC001administered intravenously per dose escalation scheme~Dose Level 1~- 60 MBq, 4 cycles every 6 weeks~Dose Level 2a~- 120 MBq, 4 to 6 cycles every 4 weeks~Dose Level 2b~- Optional cohort of 120 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3a~- 160 MBq, 4 to 6 cycles every 4 weeks~Dose Level 3b~- Optional cohort of 160 MBq, 4 to 6 cycles every 2 weeks~Dose Level 4a~- 200 MBq, 4 to 6 cycles every 4 weeks~Dose Level 4b~- Optional cohort of 200 MBq, 4 to 6 cycles every 2 weeks~Ph2a Expansion~Drug: \[²¹²Pb\]Pb-ADVC001 at recommended phase 2 dose and schedule
Study: NCT06576960
Drug: Nano silver fluoride varnish and tri calcium phosphate varnish
Normalized name: silver fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnishes
Study: NCT05360160
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05083936
Drug: [18F]FET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor
Study: NCT05429970
Drug: Etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etodolac 400 mg PO BID (for 21 consecutive days)
Study: NCT06457425
Drug: Flonoltinib 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flonoltinib 50mg
Study: NCT06457425
Drug: Flonoltinib 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flonoltinib 100mg
Study: NCT06200311
Drug: Pharmacological rhythm management
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st line: rate control, 2nd line: pharmacological rhythm management. 3rd line: AF ablation
Study: NCT04544293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05580666
Drug: Azithromycin Oral Tablet
Normalized name: azithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy
Study: NCT05426486
Drug: ARX788
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER2 antibody-drug conjugate
Study: NCT06233916
Drug: [14C] D-1553
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\] D-1553 (approximately 400 mg/80 μCi)
Study: NCT06683833
Drug: Egyptian MTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Complete caries removal from the cavity.~* The liquid of Egyptian MTA (Toothmate) will be mixed with powder according to the manufacturers' instructions.~* The capping materials will be placed with the passive application on the deepest part of the cavity. Only light pressure will be applied on the MTA mixture using a wet cotton pellet to ensure adaptation of the material onto the dentin.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities.
Study: NCT06683833
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Complete caries removal from the cavity.~* Gently tapping a capsule of Biodentine (Septodont) on a hard surface to loosen the powder, then opening the capsule, Detaching a single-dose container of liquid and gently tapping on the sealed cap to force all the liquid down the container, Twisting cap to open, Then Pouring 5 drops from the single-dose container into the capsule, Then Closing the capsule and Placing it on a mixing device for 30 seconds, Then Collecting Biodentine with the instrument supplied in the box.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities.
Study: NCT06683833
Drug: Calcium Hydroxide (Ca(OH)2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Complete caries removal from the cavity.~* According to the manufacturers' instructions, Dispensing equal volumes of base and catalyst pastes on the parchment paper pad provided. Using a Dycal (Dentsply) Liner applicator, stirring immediately to mix thoroughly until a uniform color is achieved, complete mixing occurs within 10 seconds, using the ball-pointed Dycal Liner applicator or similar instrument, the mix will be placed directly on the cavity.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities.
Study: NCT05184062
Drug: 600mg placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.
Study: NCT04791319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT06685809
Drug: FZ008-145 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose formulation- Oral tablet
Study: NCT06685809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose formulation- Matching doses
Study: NCT06697431
Drug: Intravenous Immunoglobulins, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: see previous section
Study: NCT06419686
Drug: GIP
Normalized name: GIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GIP administration during experimental days.
Study: NCT06419686
Drug: Alanine
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alanine administration during experimental days.
Study: NCT06419686
Drug: GIP + alanine
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of GIP and alanine during experimental days.
Study: NCT06085963
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredients: None Dosage form: Oral lyophilisate (referred to as allergy immunotherapy tablet in text) Excipients: Gelatine (fish source), mannitol and sodium hydroxide
Study: NCT02137525
Drug: Fentanyl 100 µg
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl sublingual spray - single unit delivering 100 µg fentanyl
Study: NCT02137525
Drug: Fentanyl 200 µg
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl sublingual spray - single unit delivering 200 µg fentanyl
Study: NCT02137525
Drug: Fentanyl 400 µg
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl sublingual spray - single unit delivering 400 µg fentanyl
Study: NCT02137525
Drug: Placebo Sublingual Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching sublingual spray - single unit delivering 0 µg fentanyl
Study: NCT06699472
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (V), intravenous injection, 1.5 mg/m2 (maximum not exceeding 2mg), D1, odd cycle administration Doxorubicin (D), intravenous infusion, 75mg/m2, D1, odd cycle administration When the cumulative dose of doxorubicin is ≥ 375mg/m2, replace it with actinomycin D 1.25mg/m2 Cyclophosphamide (C), intravenous infusion, 1200mg/m2, D1, odd cycle administration Ifosfamide (I), intravenous infusion, 1800mg/m2, D1-5, even cycle administration Etoposide (E), intravenous infusion, 100mg/m2, D1-5, even cycle administration
Study: NCT06617949
Drug: Regional Anesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transverse abdominal Plane(TAP) Block with long acting Exparel placed by a regional anesthesiologist.
Study: NCT06255392
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine tablets, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
Study: NCT06627309
Drug: Dara IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
Study: NCT06627309
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Some patients may receive cyclophosphamide orally or intravenously at a dosage of 300 mg/m2 weekly.
Study: NCT06627309
Drug: Dara SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
Study: NCT05969977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06604689
Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR-mutated NSCLC patients with brain metastases who met the inclusion and exclusion criteria, would receive first-line third-generation EGFR-TKI treatment (monotherapy or combined with upfront cranial radiotherapy)
Study: NCT06480240
Drug: OBI-992
Normalized name: phentermine hydrochloride Oral Capsule [Oby-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBI-992 is an antibody-drug conjugate
Study: NCT05113888
Drug: Qizhi weitong granules(High）
Approvals — FDA: no, EMA: no, PMDA: no
Description: take orally before meals, 1 bag each time, 3 times a day.
Study: NCT05113888
Drug: Qizhi weitong granules(Low）
Approvals — FDA: no, EMA: no, PMDA: no
Description: take orally before meals, 1 bag each time, 3 times a day.
Study: NCT05113888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: take orally before meals, 1 bag each time, 3 times a day.
Study: NCT06380699
Drug: QHRD106 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-tissue kallikrein-1
Study: NCT06380699
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06666985
Drug: ITM + Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants allocated to this group will receive ITM (Intrathecal Morphine) in addition to usual care with opioid-based PCA(Patient-Controlled Analgesia). ITM consists of an intrathecal injection of 300 micrograms (0.3mg) of preservative-free morphine.Usual care involves postoperative analgesia with opioid-based PCA without postoperative continuous infusion of opioids. No other drugs other than opioids are allowed in the PCA.
Study: NCT06666985
Drug: Sham ITM + Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sham ITM mimics the ITM procedure, but the dura is not breached.
Study: NCT04484025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo containing excipients
Study: NCT00416858
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05906563
Drug: Melatonin gel
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: local application of Melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
Study: NCT05906563
Drug: Metformin and melatonin gel
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: local application of Metformin and melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
Study: NCT05906563
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of empty nanoparticles gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack.
Study: NCT05018403
Drug: Intravenous AON-D21
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
Study: NCT05018403
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic glucose solution identical in appearance to AON-D21.
Study: NCT06186479
Drug: Aconite pain oil
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
Study: NCT06186479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
Study: NCT05121103
Drug: EZM0414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release film-coated tablets: Six dose levels starting at 100 mg, and then 200 mg, 300 mg, 400 mg, 600 mg, and 900 mg as well as an optional step-down dose level of 75 mg (if needed)
Study: NCT03865615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05673239
Drug: Levocarnitine Injection
Normalized name: levocarnitine Injection
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in the test group were injected with 1-2g (10-20mg/kg) levocarnitine on each dialysis day
Study: NCT04805060
Drug: TQB2858 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2858 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2858 is diluted with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
Study: NCT05139615
Drug: APD418
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of APD418 as an intravenous (IV) infusion.
Study: NCT04875702
Drug: Naproxen 250 MG
Normalized name: naproxen 250 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 250 mg p.o. twice daily
Study: NCT04875702
Drug: Naproxen 500 Mg
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose escalation to 500 mg twice daily for patients experiencing breakthrough flares.
Study: NCT04515706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Iguratimod
Study: NCT05519384
Drug: JK500 cell injection，cyclophosphamide，Fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: After enrollment, patients received JK500 cell injection infusion after reinduction therapy. Pretreatment regimen before cell infusion: intravenous infusion of cyclophosphamide 60mg/kg day -7, intravenous infusion of fludarabine 25mg/㎡/day day -6 to -2 days. In order to activate and expand circulating NK cells, on the day of each infusion of JK500 cells, the patients were first subcutaneously injected with 100WU/ m2 of interleukin (IL)-2 0.5h-1h in advance, for a total of 6 doses.
Study: NCT05318248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill
Study: NCT06084819
Drug: Best-Available Therapy(BAT) Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. FLAG regimen:Fludarabine(30mg/m2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~2. CLAG regimen:Cladribine(5mg/2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~3. MAE regimen:Mitox(10mg/m2,days 1 to 5)+VP-16(100mg/m2,days 1 to 5)+Cytarabine (100-150mg/m2,days 1 to 7)~4. DCAG regimen:Decitabine(20mg/m2,days 1 to 5)+Aclacinomycin(20mg/day on days 1,3,5)+Cytarabine (100mg q12h,days 1 to 5)+Granulocyte colony-stimulating factor(300 ug/day,day 0 until agranulocytosi recovery)~5. HAA regimen:HHT(2mg/m2,days 1 to 7)+Aclacinomycin(20mg/day,days 1 to 7) and Cytarabine (100-200 mg/m2, days 1 to 5);~6. HAD regimen:HHT(2mg/m2,days 1 to 7)+Daunorubicin(45mg/m2/day,days 1 to 3)+Cytarabine (100-200 mg/m2,days 1 to 5).
Study: NCT04870424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily per os the day before TAVI and once at the day of procedure. Thereafter, once daily per os up to post-procedural day 12.
Study: NCT05416476
Drug: Anisodine Hydrobromide
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anisodine Hydrobromide 1 mg oral tablet, twice times a day
Study: NCT05416476
Drug: Anisodine Hydrobromide placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anisodine Hydrobromide Placebo 1 mg oral tablet, twice times a day
Study: NCT06411925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry syrup, TID
Study: NCT06665230
Drug: MK-6552
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05531279
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.
Study: NCT04184323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will use the same vehicle for producing the active drug such as maltose without any hormones or active components
Study: NCT05375474
Drug: Oral anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-K antagonists (warfarin)
Study: NCT05375474
Drug: Single antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin